Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments

Kenji Yokoi; Tomonori Tanei; Biana Godin; Anne L. van de Ven; Masaki Hanibuchi; Aika Matsunoki; Jenolyn Alexander; Mauro Ferrari

doi:10.1016/j.canlet.2013.11.015

Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments

Kenji Yokoi, Tomonori Tanei, Biana Godin, Anne L. van de Ven, Masaki Hanibuchi, Aika Matsunoki, Jenolyn Alexander, Mauro Ferrari

Research output: Contribution to journal › Article › peer-review

53 Scopus citations

Abstract

Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy.

Original language	English (US)
Pages (from-to)	48-55
Number of pages	8
Journal	Cancer Letters
Volume	345
Issue number	1
DOIs	https://doi.org/10.1016/j.canlet.2013.11.015
State	Published - Apr 1 2014

Keywords

Biomarker
EPR effect
Nanotherapeutics
PLD
Transport oncophysics

ASJC Scopus subject areas

Cancer Research
Oncology

Access to Document

10.1016/j.canlet.2013.11.015

Cite this

@article{f1b05d273b4c43bcbe89d67589d530b0,

title = "Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments",

abstract = "Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy.",

keywords = "Biomarker, EPR effect, Nanotherapeutics, PLD, Transport oncophysics",

author = "Kenji Yokoi and Tomonori Tanei and Biana Godin and {van de Ven}, {Anne L.} and Masaki Hanibuchi and Aika Matsunoki and Jenolyn Alexander and Mauro Ferrari",

note = "Funding Information: This study was supported by the National Cancer Institute (U54CA143837). The authors thank Dr. Isaiah J. Fidler (MD Anderson Cancer Center, Houston, TX) for scientific review of the manuscript. ",

year = "2014",

month = apr,

day = "1",

doi = "10.1016/j.canlet.2013.11.015",

language = "English (US)",

volume = "345",

pages = "48--55",

journal = "Cancer Letters",

issn = "0304-3835",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments

AU - Yokoi, Kenji

AU - Tanei, Tomonori

AU - Godin, Biana

AU - van de Ven, Anne L.

AU - Hanibuchi, Masaki

AU - Matsunoki, Aika

AU - Alexander, Jenolyn

AU - Ferrari, Mauro

N1 - Funding Information: This study was supported by the National Cancer Institute (U54CA143837). The authors thank Dr. Isaiah J. Fidler (MD Anderson Cancer Center, Houston, TX) for scientific review of the manuscript.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy.

AB - Enhanced permeation and retention (EPR) effect, the mechanism by which nanotherapeutics accumulate in tumors, varies in patients based on differences in the tumor and organ microenvironment. Surrogate biomarkers for the EPR effect will aid in selecting patients who will accumulate higher amounts of nanotherapeutics and show better therapeutic efficacy. Our data suggest that the differences in the vascular permeability and pegylated liposomal doxorubicin (PLD) accumulation are tumor type as well as organ-specific and significantly correlated with the relative ratio of MMP-9 to TIMP-1 in the circulation, supporting development of these molecules as biomarkers for the personalization of nanoparticle-based therapy.

KW - Biomarker

KW - EPR effect

KW - Nanotherapeutics

KW - PLD

KW - Transport oncophysics

UR - http://www.scopus.com/inward/record.url?scp=84893793833&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893793833&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2013.11.015

DO - 10.1016/j.canlet.2013.11.015

M3 - Article

C2 - 24370567

AN - SCOPUS:84893793833

SN - 0304-3835

VL - 345

SP - 48

EP - 55

JO - Cancer Letters

JF - Cancer Letters

IS - 1

ER -

Serum biomarkers for personalization of nanotherapeutics-based therapy in different tumor and organ microenvironments

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this